antipyrine has been researched along with ono 1078 in 6 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 4 (66.67) | 29.6817 |
2010's | 2 (33.33) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
Li, W; Liu, LY; Wang, ML; Wei, EQ | 1 |
Chen, Z; Chu, LS; Mei, RH; Wei, EQ; Xu, HM; Yu, GL; Zhang, Q; Zhang, SH; Zhang, WP; Zhao, MH | 1 |
Wei, EQ; Zhang, LH | 1 |
Chen, Z; Ding, Q; Wei, EQ; Zhang, WP; Zhang, YJ | 1 |
Fang, SH; Shi, WZ; Wei, EQ; Zhang, YM; Zhao, R | 1 |
6 other study(ies) available for antipyrine and ono 1078
Article | Year |
---|---|
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
[Effects of edaravone, minocycline and ONO-1078 on oxygen/glucose deprivation-induced electrophysiological alteration in rat hippocampal slices].
Topics: Animals; Anti-Bacterial Agents; Antipyrine; Brain Ischemia; Chromones; Edaravone; Evoked Potentials; Female; Free Radical Scavengers; Glucose; Hippocampus; Leukotriene Antagonists; Minocycline; Neuroprotective Agents; Rats; Rats, Sprague-Dawley | 2004 |
Montelukast, a cysteinyl leukotriene receptor-1 antagonist, dose- and time-dependently protects against focal cerebral ischemia in mice.
Topics: Acetates; Animals; Antipyrine; Blood-Brain Barrier; Brain; Brain Edema; Brain Ischemia; Chromones; Cyclopropanes; Dose-Response Relationship, Drug; Edaravone; Free Radical Scavengers; Infarction, Middle Cerebral Artery; Leukotriene Antagonists; Mice; Nervous System; Neuroprotective Agents; Psychomotor Performance; Quinolines; Receptors, Leukotriene; Sulfides; Survival Analysis; Time Factors | 2005 |
ONO-1078 reduces NMDA-induced brain injury and vascular cell adhesion molecule-1 expression in rats.
Topics: Animals; Antipyrine; Brain; Brain Injuries; Cerebral Cortex; Chromones; Edaravone; Leukotriene Antagonists; Male; Microinjections; N-Methylaspartate; Neuroprotective Agents; Rats; Rats, Sprague-Dawley; Vascular Cell Adhesion Molecule-1 | 2005 |
Cysteinyl leukotriene receptor 1 is involved in N-methyl-D-aspartate-mediated neuronal injury in mice.
Topics: Animals; Antioxidants; Antipyrine; Brain; Brain Injuries; Chromones; Edaravone; Ketamine; Male; Membrane Proteins; Mice; N-Methylaspartate; Neurons; Receptors, Leukotriene; Receptors, N-Methyl-D-Aspartate; RNA, Messenger; Up-Regulation | 2006 |
Montelukast, a cysteinyl leukotriene receptor-1 antagonist, attenuates chronic brain injury after focal cerebral ischaemia in mice and rats.
Topics: Acetates; Administration, Oral; Animals; Antipyrine; Atrophy; Behavior, Animal; Brain Injury, Chronic; Chromones; Cyclopropanes; Disease Models, Animal; Drug Evaluation, Preclinical; Edaravone; Free Radical Scavengers; Infarction, Middle Cerebral Artery; Injections, Intraperitoneal; Leukotriene Antagonists; Male; Mice; Mice, Inbred ICR; Nerve Degeneration; Quinolines; Rats; Rats, Sprague-Dawley; Sulfides | 2011 |